888.6000 11.90 (1.36%)
NSE Jan 14, 2026 15:31 PM
Volume: 38,697
 

888.60
1.36%
BOB Capital Markets Ltd.
Q2 revenue in line at Rs 6bn but EBITDA/PAT 3%/6% below our estimates due to higher opex and a product mix change
Number of FII/FPI investors decreased from 101 to 92 in Sep 2025 qtr
More from Alivus Life Sciences Ltd.
Recommended